Crossmark

Exploration of Mechanisms of Keliu Pill on the Inhibition of Lymphangiogenesis in Non-small Cell Lung Cancer Based on Network Pharmacology and Experimental Validation

Crossref DOI link: https://doi.org/10.1007/s12010-025-05307-z

Published Online: 2026-01-21

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Shuang

Wu, Xiao

Pan, Tingyu

Zhang, Weizhou

Peng, Wenpan

Wang, Zhichao

Feng, Fanchao

Xu, Yong

Yang, Ying

He, Hailang

Zhou, Xianmei
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82074358)

Jiangsu Provincial Traditional Chinese Medicine Technology Development Plan (MS2021013)
License Information

Text and Data Mining valid from 2026-01-21

Version of Record valid from 2026-01-21
More Information

Article History

Accepted: 19 June 2025

First Online: 21 January 2026

Declarations

:

: The experiments on animals were approved by the Animal Ethical Committee of Nanjing University of Chinese Medicine (approval number: 201902A005) and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below